Sisley S, Gutierrez-Aguilar R, Scott M, D’Alessio DA, Sandoval DA, Seeley RJ. Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect. J Clin Invest. 2014;124:2456–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Secher A, Jelsing J, Baquero AF, Hecksher-Sørensen J, Cowley MA, Dalbøge LS, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124:4473–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Williams EK, Chang RB, Strochlic DE, Umans BD, Lowell BB, Liberles SD. Sensory neurons that detect stretch and nutrients in the digestive system. Cell. 2016;166:209–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nishizawa M, Nakabayashi H, Kawai K, Ito T, Kawakami S, Nakagawa A, et al. The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor. J Auton Nerv Syst. 2000;80:14–21.

Article  CAS  PubMed  Google Scholar 

Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Rønne J, Alanentalo T, Baquero AF, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight [Internet]. 2020;5. https://doi.org/10.1172/jci.insight.133429

Bakker W, Imbernon M, Salinas CG, Moro Chao DH, Hassouna R, Morel C, et al. Acute changes in systemic glycemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis. Cell Rep. 2022;41: 111698.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Imbernon M, Saponaro C, Helms HCC, Duquenne M, Fernandois D, Deligia E, et al. Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions. Cell Metab. 2022;34:1054-1063.e7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim KS, Park JS, Hwang E, Park MJ, Shin HY, Lee YH, et al. GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans. Science. 2024;385:438–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang K-P, Acosta AA, Ghidewon MY, McKnight AD, Almeida MS, Nyema NT, et al. Dissociable hindbrain GLP1R circuits for satiety and aversion. Nature. 2024;632:585–93.

Article  PubMed  Google Scholar 

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11–22.

Article  PubMed  Google Scholar 

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002.

Article  CAS  PubMed  Google Scholar 

Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sørrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial: The STEP 8 randomized clinical trial. JAMA. 2022;327:138–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davies M, Pieber TR, Hartoft-Nielsen M-L, Hansen OKH, Jabbour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318:1460–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sikirica MV, Martin AA, Wood R, Leith A, Piercy J, Higgins V. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy [Internet]. 2017 [cited 2025 Jan 27]; Available from: https://doi.org/10.2147/DMSO.S141235.

Hall KD, Kahan S. Maintenance of lost weight and long-term management of obesity. Med Clin North Am. 2018;102:183–97.

Article  PubMed  PubMed Central  Google Scholar 

Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19:1242–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li J-R, Cao J, Wei J, Geng W. Case Report: Semaglutide-associated depression: a report of two cases. Front Psychiatry. 2023;14:1238353.

Article  PubMed  PubMed Central  Google Scholar 

Tempia Valenta S, Nicastri A, Perazza F, Marcolini F, Beghelli V, Atti AR, et al. The impact of GLP-1 receptor agonists (GLP-1 RAs) on mental health: a systematic review. Curr Treat Options Psychiatry. 2024;11:310–57.

Article  Google Scholar 

Hayes MR, Schmidt HD. GLP-1 influences food and drug reward. Curr Opin Behav Sci. 2016;9:66–70.

Article  PubMed  PubMed Central  Google Scholar 

Klausen MK, Jensen ME, Møller M, Le Dous N, Jensen A-MØ, Zeeman VA, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight [Internet]. 2022 [cited 2024 Oct 14];7. Available from: http://insight.jci.org/articles/view/159863/files/pdf

Hernandez NS, Schmidt HD. Central GLP-1 receptors: Novel molecular targets for cocaine use disorder. Physiol Behav. 2019;206:93–105.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guyenet SJ, Schwartz MW. Clinical review: Regulation of food intake, energy balance, and body fat mass: implications for the pathogenesis and treatment of obesity. J Clin Endocrinol Metab. 2012;97:745–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009;5:749–57.

Article  CAS  PubMed  Google Scholar 

Finan B, Ma T, Ottaway N, Müller TD, Habegger KM, Heppner KM, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013;5:209ra151.

Campbell JE. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms Mol Metab. 2021;46: 101139.

Article  CAS  PubMed  Google Scholar 

Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

El K, Douros JD, Willard FS, Novikoff A, Sargsyan A, Perez-Tilve D, et al. The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. Nat Metab. 2023;5:945–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503–15.

Article  PubMed  Google Scholar 

Borner T, Geisler CE, Fortin SM, Cosgrove R, Alsina-Fernandez J, Dogra M, et al. GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and Emesis in preclinical models. Diabetes. 2021;70:2545–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adriaenssens AE, Biggs EK, Darwish T, Tadross J, Sukthankar T, Girish M, et al. Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake. Cell Metab. 2019;30:987-996.e6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Samms RJ, Christe ME, Collins KA, Pirro V, Droz BA, Holland AK, et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J Clin Invest [Internet]. 2021;131 https://doi.org/10.1172/JCI146353.

Mroz PA, Finan B, Gelfanov V, Yang B, Tschöp MH, DiMarchi RD, et al. Optimized